Cargando…
Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627529/ https://www.ncbi.nlm.nih.gov/pubmed/36341890 http://dx.doi.org/10.1016/j.jinf.2022.10.015 |
| _version_ | 1784822991048146944 |
|---|---|
| author | Mashimo, Yoichi Yamazaki, Keiko Kageyama, Takahiro Tanaka, Shigeru Taniguchi, Toshibumi Matsushita, Kazuyuki Igari, Hidetoshi Hanaoka, Hideki Yokote, Koutaro Nakajima, Hiroshi Onouchi, Yoshihiro |
| author_facet | Mashimo, Yoichi Yamazaki, Keiko Kageyama, Takahiro Tanaka, Shigeru Taniguchi, Toshibumi Matsushita, Kazuyuki Igari, Hidetoshi Hanaoka, Hideki Yokote, Koutaro Nakajima, Hiroshi Onouchi, Yoshihiro |
| author_sort | Mashimo, Yoichi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9627529 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96275292022-11-02 Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine Mashimo, Yoichi Yamazaki, Keiko Kageyama, Takahiro Tanaka, Shigeru Taniguchi, Toshibumi Matsushita, Kazuyuki Igari, Hidetoshi Hanaoka, Hideki Yokote, Koutaro Nakajima, Hiroshi Onouchi, Yoshihiro J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-12 2022-11-02 /pmc/articles/PMC9627529/ /pubmed/36341890 http://dx.doi.org/10.1016/j.jinf.2022.10.015 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Mashimo, Yoichi Yamazaki, Keiko Kageyama, Takahiro Tanaka, Shigeru Taniguchi, Toshibumi Matsushita, Kazuyuki Igari, Hidetoshi Hanaoka, Hideki Yokote, Koutaro Nakajima, Hiroshi Onouchi, Yoshihiro Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine |
| title | Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine |
| title_full | Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine |
| title_fullStr | Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine |
| title_full_unstemmed | Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine |
| title_short | Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine |
| title_sort | germline variants of ighv3-53 / v3-66 are determinants of antibody responses to the bnt162b2 mrna covid-19 vaccine |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627529/ https://www.ncbi.nlm.nih.gov/pubmed/36341890 http://dx.doi.org/10.1016/j.jinf.2022.10.015 |
| work_keys_str_mv | AT mashimoyoichi germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT yamazakikeiko germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT kageyamatakahiro germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT tanakashigeru germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT taniguchitoshibumi germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT matsushitakazuyuki germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT igarihidetoshi germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT hanaokahideki germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT yokotekoutaro germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT nakajimahiroshi germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine AT onouchiyoshihiro germlinevariantsofighv353v366aredeterminantsofantibodyresponsestothebnt162b2mrnacovid19vaccine |